Thrombocytopenia; He reported to ER 10Feb2023 with complaints of frequent nose bleeds; Bruising starting on 08Feb2023; This is a spontaneous report received from contactable reporter(s) (Nurse).  A 46-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Feb2023 as dose 3 (booster), single (Lot number: GK0928) intramuscular, in right arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: EW0185, Location of injection: Arm Right, Route of Administration: Intramuscular), administration date: 13May2021, for COVID-19 immunisation; BNT162b2 (Dose Number: 2, Batch/Lot No: 33030BD, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 21Dec2021, for COVID-19 immunisation, reaction(s): "Inappropriate schedule of vaccine administered". The following information was reported: CONTUSION (hospitalization, life threatening) with onset 08Feb2023, outcome "recovering", described as "Bruising starting on 08Feb2023"; EPISTAXIS (hospitalization, life threatening) with onset 08Feb2023, outcome "recovering", described as "He reported to ER 10Feb2023 with complaints of frequent nose bleeds"; THROMBOCYTOPENIA (hospitalization, life threatening) with onset 08Feb2023, outcome "recovering". The patient was hospitalized for epistaxis, contusion (hospitalization duration: 14 day(s)); the patient was hospitalized for thrombocytopenia (hospitalization duration: 14 day(s)). The events "thrombocytopenia", "he reported to er 10feb2023 with complaints of frequent nose bleeds" and "bruising starting on 08feb2023" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: Full blood count: platelets less than 2. Therapeutic measures were taken as a result of thrombocytopenia, epistaxis, contusion. Clinical course: Healthcare Professional reporting for a patient. Facility type vaccine: Pharmacy or Drug Store. Patient was not administered with other vaccine in four weeks. He reported to emergency room 10Feb2023 with complaints of frequent nose bleeds and bruising starting on 08Feb2023. CBC/d (Complete blood count) date showed platelets less than 2. Patient had required 2 hospital stays and emergent intervention for life-threatening thrombocytopenia. He had to receive courses of IV (Intravenous) and oral steroids, IVIG (Intravenous Immunoglobulin) and rituxumab to assist with platelet count recovery. If treatment adverse event: Yes. Adverse event treatment: IV Steroids, Oral Steroid, IV Immunoglobulin, IV Rituxmab. Patient was not covid tested post vaccination. There were no Known allergies: No.; Sender's Comments: Based on the temporal relationship, a possible contributory role of BNT162B2, BNT162B2 OMI BA.4-5 cannot be excluded for the reported events Thrombocytopenia, Epistaxis and Contusion.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.